News

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

-- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of building and leading high performing operating teams and financing in the capital markets with over $1B+ raised and multiple company exits by acquisition -- CID-103 is a potential best in class, anti-CD38 monoclonal antibody, currently dosing in a multi-center Phase 1/2 study in adults with chronic immune thrombocytopenia (ITP); IND submitted to support future clinical trials in adults with renal allograft antibody-mediated rejection (AMR) BEIJING, CN / ACCESS Newswire / July 21, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the appointment of David Cory as Chief Executive Officer and a member of the Board of Directors. Wei-Wu He, Ph.D.

07/21/2025

CASI Pharmaceuticals Provides Business and Clinical Update

BEIJING, CHINA / ACCESS Newswire / May 19, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that it will host a live conference call and webcast at 8:00 a.m. PT/11:00 a.m.

05/19/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is CASI Pharmaceuticals, Inc. (CASI) a buy, sell, or hold?

CASI Pharmaceuticals, Inc. (CASI) can sell. Click on Rating Page for detail.

What is CASI Pharmaceuticals, Inc.'s stock price?

The price of CASI Pharmaceuticals, Inc. (CASI) is 1.29 and it was updated on 2025-08-03 07:00:19.

Is CASI Pharmaceuticals, Inc. (CASI) overvalued or undervalued?

Currently CASI Pharmaceuticals, Inc. (CASI) is in undervalued.

News

From:

To:

News
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results BEIJING, CN / ACCESS Newswire / May 16, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the quarter ended March 31, 2025. Dr. Wei-Wu He, Ph.D. Fri, May. 16, 2025
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China BEIJING, CHINA / ACCESS Newswire / May 12, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has entered into a definitive Equity and Assets Transfer Agreement (the "Equity and Assets Transfer Agreement") with Kaixin Pharmaceuticals Inc. ("Kaixin Pharmaceuticals"), a Cayman Islands incorporated entity wholly-owned by Dr. Wei-Wu He, Chairman of the board of directors and CEO of the Company and two direct wholly-owned subsidiaries of the Company in China (the "Target Companies"), pursuant to which the Company shall sell and transfer, and Kaixin Pharmaceuticals shall purchase and acquire, 100% equity interests in both Target Companies (the "Target Equity Interests"), and all licensing rights, distribution rights, supply arrangements and related rights related to BI-1206 (in China), CID-103(in Asia excluding Japan) and Thiotepa (in China excluding Hong Kong, Macau and Taiwan) (the "Target Pipeline Products") for an aggregate purchase price of $20.0 million, which shall include assumption of up to $20.0 million of indebtedness of the Company (the "Transaction"). The closing of the Transaction shall be subject to certain customary conditions, including resolution of certain judicial freeze on the Target Equity Interests issued in connection with certain ongoing legal dispute of the Company. Mon, May. 12, 2025
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement BEIJING, CHINA / ACCESS Newswire / May 7, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") dated May 5, 2025 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities ("MVLS") of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum MVLS of $35 million (the "MVLS Requirement"), and Nasdaq Listing Rule 5810(c)(3)(C) specifies that a deficiency occurs if the MVLS falls below this threshold for 30 consecutive business days. Wed, May. 07, 2025
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company BEIJING, CN / ACCESS Newswire / April 3, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI, "CASI"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that its special committee of the board of directors (the "Special Committee") has received an updated preliminary non-binding proposal letter (the "Proposal Letter"), dated April 2, 2025, from Dr. Wei-Wu He, Chairman of the board of directors and CEO of the Company, to acquire the entire business operations of the Company in China and all license-in, distribution and related rights in Asia (excluding Japan) related to certain pipeline products of the Company, including BI-1206, CID-103 and Thiotepa, for an aggregate purchase price of $20.0 million, which shall include assumption of approximately $20.0 million of indebtedness of the Company (the "Proposed Transaction"). The Proposal Letter updates the preliminary non-binding proposal letter submitted by Dr. He to the Company on June 21, 2024. Thu, Apr. 03, 2025
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the fourth quarter ended December 31, 2024, and provided an update on key highlights for 2024. Wei-Wu He, Ph.D. Mon, Mar. 31, 2025

Transcripts

Transcipts Data
CASI Pharmaceuticals, Inc. (CASI) on Q2 2022 Results - Earnings Call Transcript SA Transcripts Fri, Aug. 12, 2022
CASI Pharmaceuticals, Inc. (CASI) on Q1 2022 Results - Earnings Call Transcript SA Transcripts Thu, May. 12, 2022
CASI Pharmaceuticals, Inc. (CASI) on Q4 2021 Results - Earnings Call Transcript SA Transcripts Mon, Mar. 28, 2022
CASI Pharmaceuticals, Inc. (CASI) on Q3 2021 Results - Earnings Call Transcript SA Transcripts Fri, Nov. 12, 2021
CASI Pharmaceuticals, Inc. (CASI) on Q2 2021 Results - Earnings Call Transcript SA Transcripts Fri, Aug. 13, 2021
CASI Pharmaceuticals, Inc. (CASI) on Q1 2021 Results - Earnings Call Transcript SA Transcripts Wed, May. 19, 2021

SEC Filings

SEC Filings
CASI Pharmaceuticals, Inc. (CASI) - SCHEDULE 13D/A SEC Filings 06/20/2025
CASI Pharmaceuticals, Inc. (CASI) - 6-K/A - Current report SEC Filings 05/20/2025
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 05/20/2025
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 05/16/2025
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 05/14/2025
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 05/12/2025
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 05/07/2025
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 04/09/2025
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 04/03/2025
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 04/01/2025
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 03/31/2025
CASI Pharmaceuticals, Inc. (CASI) - 20-F SEC Filings 03/31/2025
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 02/10/2025
CASI Pharmaceuticals, Inc. (CASI) - SCHEDULE 13D/A SEC Filings 02/03/2025
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 01/21/2025
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 01/02/2025
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 12/26/2024
CASI Pharmaceuticals, Inc. (CASI) - F-3/A SEC Filings 12/23/2024
CASI Pharmaceuticals, Inc. (CASI) - F-3 SEC Filings 12/20/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 12/16/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 11/15/2024
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 10/29/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 09/12/2024
CASI Pharmaceuticals, Inc. (CASI) - F-3/A SEC Filings 08/29/2024
CASI Pharmaceuticals, Inc. (CASI) - F-3 SEC Filings 08/16/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 08/16/2024
CASI Pharmaceuticals, Inc. (CASI) - S-8 SEC Filings 08/14/2024
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 08/12/2024
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 07/25/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 07/19/2024
CASI Pharmaceuticals, Inc. (CASI) - D SEC Filings 07/15/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 07/08/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 06/27/2024
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 06/20/2024
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 06/11/2024
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 06/10/2024
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 05/30/2024
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 05/22/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 05/15/2024
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 05/13/2024
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 05/09/2024
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 05/08/2024
CASI Pharmaceuticals, Inc. (CASI) - F-3 SEC Filings 05/03/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 04/08/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 03/28/2024
CASI Pharmaceuticals, Inc. (CASI) - 20-F SEC Filings 03/28/2024
CASI Pharmaceuticals, Inc. (CASI) - 144 SEC Filings 03/15/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 03/13/2024
CASI Pharmaceuticals, Inc. (CASI) - 144 SEC Filings 03/05/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 02/29/2024
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 02/20/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 02/12/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 01/30/2024
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 01/26/2024
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 12/15/2023
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 12/08/2023
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 11/14/2023
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 11/09/2023
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 11/08/2023
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 09/19/2023
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 08/25/2023
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 08/14/2023
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 08/11/2023
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 08/01/2023
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 07/20/2023
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 06/23/2023
CASI Pharmaceuticals, Inc. (CASI) - S-8 POS SEC Filings 05/23/2023
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 05/17/2023
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 04/26/2023
CASI Pharmaceuticals, Inc. (CASI) - 20-F SEC Filings 04/26/2023
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 04/18/2023
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 04/10/2023
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 03/27/2023
CASI Pharmaceuticals, Inc. (CASI) - 8-A12B SEC Filings 03/27/2023
CASI Pharmaceuticals, Inc. (CASI) - 15-12G SEC Filings 03/22/2023
CASI Pharmaceuticals, Inc. (CASI) - S-8 POS SEC Filings 03/21/2023
CASI Pharmaceuticals, Inc. (CASI) - POS AM SEC Filings 03/21/2023
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/21/2023
CASI Pharmaceuticals, Inc. (CASI) - 6-K - Current report SEC Filings 03/21/2023
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 02/21/2023
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 02/14/2023
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 02/14/2023
CASI Pharmaceuticals, Inc. (CASI) - 424B3 SEC Filings 02/14/2023
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/09/2023
CASI Pharmaceuticals, Inc. (CASI) - F-4/A SEC Filings 02/09/2023
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 02/09/2023
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 02/08/2023
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/01/2023
CASI Pharmaceuticals, Inc. (CASI) - F-4 SEC Filings 01/31/2023
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/31/2023
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/14/2022
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/14/2022
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/23/2022
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 09/08/2022
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 09/02/2022
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 08/26/2022
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 08/23/2022
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/12/2022
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/12/2022
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 06/21/2022
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/17/2022
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/26/2022
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 05/26/2022
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/25/2022
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/24/2022
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/12/2022
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/12/2022
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/02/2022
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/15/2022
CASI Pharmaceuticals, Inc. (CASI) - PRE 14A SEC Filings 04/04/2022
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/28/2022
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/28/2022
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/04/2022
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/16/2022
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/14/2022
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/03/2022
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/17/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/10/2021
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 12/06/2021
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 11/23/2021
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 11/19/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/12/2021
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/12/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 10/29/2021
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 10/29/2021
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 08/20/2021
CASI Pharmaceuticals, Inc. (CASI) - S-8 POS SEC Filings 08/13/2021
CASI Pharmaceuticals, Inc. (CASI) - S-8 SEC Filings 08/13/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/12/2021
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/12/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 07/28/2021
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 07/26/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K/A - Current report SEC Filings 06/21/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/16/2021
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/16/2021
CASI Pharmaceuticals, Inc. (CASI) - DEFA14A SEC Filings 06/07/2021
CASI Pharmaceuticals, Inc. (CASI) - PX14A6G SEC Filings 06/02/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/13/2021
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/13/2021
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 05/10/2021
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 04/30/2021
CASI Pharmaceuticals, Inc. (CASI) - PRE 14A SEC Filings 04/30/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 04/30/2021
CASI Pharmaceuticals, Inc. (CASI) - 10-K/A - Current report SEC Filings 04/29/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/30/2021
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/30/2021
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/30/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/26/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/25/2021
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 03/25/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/23/2021
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 03/23/2021
CASI Pharmaceuticals, Inc. (CASI) - SEC STAFF LETTER SEC Filings 03/18/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/12/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/08/2021
CASI Pharmaceuticals, Inc. (CASI) - SEC STAFF LETTER SEC Filings 02/18/2021
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 02/17/2021
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 02/16/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/16/2021
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 02/12/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/10/2021
CASI Pharmaceuticals, Inc. (CASI) - 10-Q/A - Quarterly Report SEC Filings 02/10/2021
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 02/03/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/28/2021
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/23/2020
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 12/23/2020
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 12/18/2020
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 12/18/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/16/2020
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 12/03/2020
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 12/02/2020
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 11/30/2020
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 11/27/2020
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 11/24/2020
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 11/20/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/19/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/09/2020
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/09/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 10/28/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/28/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/02/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/19/2020
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 08/18/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/10/2020
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/10/2020
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 07/29/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 07/24/2020
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 07/24/2020
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 07/23/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 07/21/2020
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 07/21/2020
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/18/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/17/2020
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 05/21/2020
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 05/19/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/12/2020
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/11/2020
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/22/2020
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/30/2020
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/27/2020
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 03/24/2020
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/19/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/16/2020
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/16/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/06/2020
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/20/2020
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/19/2020
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/06/2020
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 12/18/2019
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 12/17/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/26/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/13/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/12/2019
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/12/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/01/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K/A - Current report SEC Filings 09/25/2019
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 09/24/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/11/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/23/2019
CASI Pharmaceuticals, Inc. (CASI) - CT ORDER SEC Filings 08/20/2019
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 08/20/2019
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 08/15/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/09/2019
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 08/09/2019
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/09/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 07/19/2019
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 07/19/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/21/2019
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/21/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/18/2019
CASI Pharmaceuticals, Inc. (CASI) - CT ORDER SEC Filings 06/06/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/15/2019
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/15/2019
CASI Pharmaceuticals, Inc. (CASI) - NT 10-Q - Quarterly Report SEC Filings 05/10/2019
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/30/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 04/17/2019
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 04/11/2019
CASI Pharmaceuticals, Inc. (CASI) - PRE 14A SEC Filings 04/05/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 04/05/2019
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 04/04/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/29/2019
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/29/2019
CASI Pharmaceuticals, Inc. (CASI) - NT 10-K - Current report SEC Filings 03/18/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/13/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/19/2019
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/06/2019
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 02/06/2019
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 02/06/2019
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/31/2019
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/29/2019
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/15/2019
CASI Pharmaceuticals, Inc. (CASI) - S-8 SEC Filings 12/21/2018
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 12/21/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/06/2018
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 12/06/2018
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 11/30/2018
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 11/27/2018
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 11/21/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/20/2018
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 11/14/2018
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 11/14/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/14/2018
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 11/14/2018
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/14/2018
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 10/31/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K/A - Current report SEC Filings 10/24/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 10/24/2018
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 10/11/2018
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 10/02/2018
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 10/02/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 10/01/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/28/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/14/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/14/2018
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/14/2018
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 08/09/2018
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 08/06/2018
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 08/06/2018
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 07/23/2018
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 07/17/2018
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 07/13/2018
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 07/03/2018
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/12/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/11/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/15/2018
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/15/2018
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 05/14/2018
CASI Pharmaceuticals, Inc. (CASI) - CT ORDER SEC Filings 04/23/2018
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/17/2018
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 04/13/2018
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 04/06/2018
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 04/04/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/29/2018
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/29/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/23/2018
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/23/2018
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/21/2018
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 03/20/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/16/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/23/2018
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 02/23/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/09/2018
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 02/06/2018
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 02/01/2018
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 02/01/2018
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/26/2018
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 01/25/2018
CASI Pharmaceuticals, Inc. (CASI) - SC 13D SEC Filings 01/12/2018
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 12/26/2017
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/22/2017
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 12/22/2017
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 12/21/2017
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 12/21/2017
CASI Pharmaceuticals, Inc. (CASI) - S-8 SEC Filings 12/13/2017
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 12/13/2017
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/08/2017
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 12/01/2017
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/14/2017
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/14/2017
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 10/19/2017
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 10/17/2017
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 10/11/2017
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 10/10/2017
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 10/06/2017
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 10/03/2017
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 09/20/2017
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 09/18/2017
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/07/2017
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/14/2017
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/14/2017
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/09/2017
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/09/2017
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/15/2017
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/15/2017
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/14/2017
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 04/05/2017
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 04/05/2017
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/31/2017
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/31/2017
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 03/03/2017
CASI Pharmaceuticals, Inc. (CASI) - 424B3 SEC Filings 01/20/2017
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 12/22/2016
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 12/19/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/16/2016
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 12/14/2016
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 12/05/2016
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 12/02/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/14/2016
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/14/2016
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 11/01/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 10/25/2016
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 10/25/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 10/05/2016
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 10/05/2016
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 08/16/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/15/2016
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/15/2016
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 07/06/2016
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 06/30/2016
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/29/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/27/2016
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/27/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/03/2016
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/03/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/13/2016
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/13/2016
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/08/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/31/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/28/2016
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/28/2016
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 03/21/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/18/2016
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/11/2016
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/04/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/17/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/10/2016
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/27/2016
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 01/27/2016
CASI Pharmaceuticals, Inc. (CASI) - SC 13D SEC Filings 01/25/2016
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 01/25/2016
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/21/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/19/2016
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/13/2015
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/13/2015
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 10/16/2015
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 10/14/2015
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 10/14/2015
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 10/06/2015
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 10/01/2015
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/22/2015
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/14/2015
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/14/2015
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/08/2015
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/15/2015
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/15/2015
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/17/2015
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 04/08/2015
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/27/2015
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/27/2015
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 02/09/2015
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 02/04/2015
CASI Pharmaceuticals, Inc. (CASI) - CT ORDER SEC Filings 01/29/2015
CASI Pharmaceuticals, Inc. (CASI) - 10-Q/A - Quarterly Report SEC Filings 01/21/2015
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 12/23/2014
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 12/12/2014
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/12/2014
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/05/2014
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/14/2014
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 11/14/2014
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/14/2014
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 10/17/2014
CASI Pharmaceuticals, Inc. (CASI) - PRE 14A SEC Filings 10/03/2014
CASI Pharmaceuticals, Inc. (CASI) - SC 13D SEC Filings 09/26/2014
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 09/25/2014
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/23/2014
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 09/23/2014
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 09/23/2014
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/19/2014
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/14/2014
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/14/2014
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/13/2014
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/03/2014
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/03/2014
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 06/03/2014
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/15/2014
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/15/2014
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/21/2014
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 04/04/2014
CASI Pharmaceuticals, Inc. (CASI) - PRE 14A SEC Filings 03/27/2014
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/21/2014
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/21/2014
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/19/2014
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 01/08/2014
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/14/2013
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/14/2013
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/14/2013
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/14/2013
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/03/2013
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 05/31/2013
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/15/2013
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/15/2013
CASI Pharmaceuticals, Inc. (CASI) - S-8 SEC Filings 04/19/2013
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/16/2013
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 04/12/2013
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 04/11/2013
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 04/09/2013
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/21/2013
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/21/2013
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 03/06/2013
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 03/06/2013
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/06/2013
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 03/04/2013
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/14/2012
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/14/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/01/2012
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 10/10/2012
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 09/27/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/20/2012
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 08/17/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/14/2012
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/14/2012
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 08/09/2012
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 08/09/2012
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 07/23/2012
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 06/11/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/23/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/15/2012
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/15/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/04/2012
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 05/03/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 04/03/2012
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 04/03/2012
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 04/03/2012
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 03/22/2012
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/14/2012
CASI Pharmaceuticals, Inc. (CASI) - PRE 14A SEC Filings 03/12/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/09/2012
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/09/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/07/2012
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/02/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/23/2012
CASI Pharmaceuticals, Inc. (CASI) - D SEC Filings 02/15/2012
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 02/13/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/06/2012
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 02/02/2012
CASI Pharmaceuticals, Inc. (CASI) - SC 13D SEC Filings 01/30/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/26/2012
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/25/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/06/2012
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/28/2011
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/14/2011
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/14/2011
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/15/2011
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/15/2011
CASI Pharmaceuticals, Inc. (CASI) - 424B2 SEC Filings 08/05/2011
CASI Pharmaceuticals, Inc. (CASI) - 424B2 SEC Filings 07/29/2011
CASI Pharmaceuticals, Inc. (CASI) - 424B2 SEC Filings 07/22/2011
CASI Pharmaceuticals, Inc. (CASI) - 424B2 SEC Filings 07/15/2011
CASI Pharmaceuticals, Inc. (CASI) - 424B2 SEC Filings 07/08/2011
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/28/2011
CASI Pharmaceuticals, Inc. (CASI) - 424B2 SEC Filings 06/28/2011
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/21/2011
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/10/2011
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/16/2011
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/16/2011
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/28/2011
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/30/2011
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/30/2011
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/14/2011
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/31/2011
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/12/2011
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 01/12/2011
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/22/2010
CASI Pharmaceuticals, Inc. (CASI) - CT ORDER SEC Filings 11/23/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/12/2010
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/12/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/10/2010
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 09/08/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/20/2010
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/16/2010
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 07/14/2010
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 07/13/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 07/07/2010
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 06/24/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/08/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/18/2010
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/17/2010
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/29/2010
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 04/27/2010
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 04/27/2010
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 04/26/2010
CASI Pharmaceuticals, Inc. (CASI) - PRE 14A SEC Filings 04/19/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 04/16/2010
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 04/16/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 04/09/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 04/07/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/29/2010
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/29/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/24/2010
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 02/11/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/04/2010
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 02/04/2010
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/28/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/20/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/12/2010
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 01/12/2010
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/15/2009
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/16/2009
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/16/2009
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 10/13/2009
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 08/06/2009
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/06/2009
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/06/2009
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/06/2009
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/06/2009
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/29/2009
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/13/2009
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/12/2009
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 03/09/2009
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 02/04/2009
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/02/2009
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/29/2009
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 12/29/2008
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/17/2008
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/10/2008
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/07/2008
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 10/03/2008
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 09/17/2008
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/06/2008
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 07/14/2008
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 06/25/2008
CASI Pharmaceuticals, Inc. (CASI) - EFFECT SEC Filings 06/24/2008
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 06/20/2008
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 06/19/2008
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 06/19/2008
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/19/2008
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 06/19/2008
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 06/16/2008
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 06/10/2008
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/06/2008
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/06/2008
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/05/2008
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/02/2008
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/22/2008
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 04/15/2008
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 04/07/2008
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/25/2008
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/24/2008
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 03/20/2008
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/06/2008
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/06/2008
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/07/2008
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/03/2008
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 12/21/2007
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 12/14/2007
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/12/2007
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/23/2007
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/08/2007
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/06/2007
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 10/29/2007
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 10/17/2007
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 10/17/2007
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 10/16/2007
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 10/04/2007
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 09/18/2007
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 09/17/2007
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 08/31/2007
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/08/2007
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/08/2007
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/18/2007
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/09/2007
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/09/2007
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/27/2007
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 04/17/2007
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/15/2007
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/13/2007
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/07/2007
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/22/2007
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/17/2007
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/28/2006
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 12/20/2006
CASI Pharmaceuticals, Inc. (CASI) - 424B3 SEC Filings 12/14/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/13/2006
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 12/13/2006
CASI Pharmaceuticals, Inc. (CASI) - 424B3 SEC Filings 12/13/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/14/2006
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/06/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/09/2006
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/09/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/22/2006
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/19/2006
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/14/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/06/2006
CASI Pharmaceuticals, Inc. (CASI) - 424B3 SEC Filings 06/05/2006
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/02/2006
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 06/02/2006
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 05/12/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/12/2006
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/10/2006
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 05/08/2006
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 05/08/2006
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 05/05/2006
CASI Pharmaceuticals, Inc. (CASI) - PRE 14A SEC Filings 05/02/2006
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 04/10/2006
CASI Pharmaceuticals, Inc. (CASI) - 424B3 SEC Filings 04/07/2006
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 04/05/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K/A - Current report SEC Filings 04/04/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K/A - Current report SEC Filings 03/29/2006
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 03/24/2006
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/14/2006
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 03/13/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/09/2006
CASI Pharmaceuticals, Inc. (CASI) - REGDEX SEC Filings 02/22/2006
CASI Pharmaceuticals, Inc. (CASI) - REGDEX SEC Filings 02/21/2006
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/14/2006
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 02/09/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/08/2006
CASI Pharmaceuticals, Inc. (CASI) - REGDEX SEC Filings 01/19/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/17/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/13/2006
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/29/2005
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 12/28/2005
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/23/2005
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 12/08/2005
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 12/07/2005
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/09/2005
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/07/2005
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 10/27/2005
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/09/2005
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/02/2005
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 07/29/2005
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 06/27/2005
CASI Pharmaceuticals, Inc. (CASI) - CORRESP SEC Filings 06/23/2005
CASI Pharmaceuticals, Inc. (CASI) - UPLOAD SEC Filings 06/22/2005
CASI Pharmaceuticals, Inc. (CASI) - PRE 14A SEC Filings 06/15/2005
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/24/2005
CASI Pharmaceuticals, Inc. (CASI) - 10-Q/A - Quarterly Report SEC Filings 05/24/2005
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/10/2005
CASI Pharmaceuticals, Inc. (CASI) - 10-K/A - Current report SEC Filings 05/09/2005
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 04/07/2005
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 04/04/2005
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 04/01/2005
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/29/2005
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/16/2005
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 03/11/2005
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/23/2005
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 02/18/2005
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 02/18/2005
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/11/2005
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 01/26/2005
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 01/26/2005
CASI Pharmaceuticals, Inc. (CASI) - REGDEX SEC Filings 01/13/2005
CASI Pharmaceuticals, Inc. (CASI) - 4/A SEC Filings 01/13/2005
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 01/12/2005
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/29/2004
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 12/22/2004
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/06/2004
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 12/03/2004
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/09/2004
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 09/27/2004
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 09/10/2004
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 09/07/2004
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/09/2004
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/03/2004
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 07/15/2004
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/18/2004
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 06/17/2004
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 06/16/2004
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 05/07/2004
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/05/2004
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 04/29/2004
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 04/27/2004
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 03/26/2004
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/15/2004
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/20/2004
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/17/2004
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 02/04/2004
CASI Pharmaceuticals, Inc. (CASI) - 4/A SEC Filings 12/19/2003
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 11/19/2003
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 11/13/2003
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/13/2003
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 11/10/2003
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/07/2003
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 11/04/2003
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 10/23/2003
CASI Pharmaceuticals, Inc. (CASI) - 4 SEC Filings 10/22/2003
CASI Pharmaceuticals, Inc. (CASI) - 3 SEC Filings 10/22/2003
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/12/2003
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 07/31/2003
CASI Pharmaceuticals, Inc. (CASI) - ARS SEC Filings 06/20/2003
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 05/23/2003
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 05/21/2003
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 05/20/2003
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/15/2003
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 04/28/2003
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 04/25/2003
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 04/25/2003
CASI Pharmaceuticals, Inc. (CASI) - 10-K/A - Current report SEC Filings 04/25/2003
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 04/08/2003
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/31/2003
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 01/15/2003
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 01/10/2003
CASI Pharmaceuticals, Inc. (CASI) - SC 13D SEC Filings 01/03/2003
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 01/02/2003
CASI Pharmaceuticals, Inc. (CASI) - S-8 SEC Filings 12/02/2002
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/14/2002
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 09/27/2002
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/14/2002
CASI Pharmaceuticals, Inc. (CASI) - DEFA14A SEC Filings 05/30/2002
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 05/17/2002
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/15/2002
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 05/09/2002
CASI Pharmaceuticals, Inc. (CASI) - PRE 14A SEC Filings 05/07/2002
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 03/18/2002
CASI Pharmaceuticals, Inc. (CASI) - 10-K/A - Current report SEC Filings 03/18/2002
CASI Pharmaceuticals, Inc. (CASI) - 8-K/A - Current report SEC Filings 03/15/2002
CASI Pharmaceuticals, Inc. (CASI) - 10-Q/A - Quarterly Report SEC Filings 03/15/2002
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 03/13/2002
CASI Pharmaceuticals, Inc. (CASI) - 10-K405 - Current report SEC Filings 03/12/2002
CASI Pharmaceuticals, Inc. (CASI) - 8-K/A - Current report SEC Filings 03/11/2002
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 02/25/2002
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/14/2002
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/01/2002
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 01/16/2002
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 12/19/2001
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/13/2001
CASI Pharmaceuticals, Inc. (CASI) - S-8 SEC Filings 08/21/2001
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/14/2001
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 05/23/2001
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/15/2001
CASI Pharmaceuticals, Inc. (CASI) - 10-K/A - Current report SEC Filings 04/30/2001
CASI Pharmaceuticals, Inc. (CASI) - 10-K - Current report SEC Filings 03/30/2001
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 02/28/2001
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/27/2001
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/16/2001
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 02/13/2001
CASI Pharmaceuticals, Inc. (CASI) - 424B3 SEC Filings 02/08/2001
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/13/2000
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/11/2000
CASI Pharmaceuticals, Inc. (CASI) - S-8 SEC Filings 07/12/2000
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/15/2000
CASI Pharmaceuticals, Inc. (CASI) - 424B5 SEC Filings 06/15/2000
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 06/13/2000
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 05/19/2000
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/12/2000
CASI Pharmaceuticals, Inc. (CASI) - 10-K/A - Current report SEC Filings 05/01/2000
CASI Pharmaceuticals, Inc. (CASI) - 424B3 SEC Filings 03/31/2000
CASI Pharmaceuticals, Inc. (CASI) - 10-K405 - Current report SEC Filings 03/30/2000
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/11/2000
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 01/14/2000
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/12/1999
CASI Pharmaceuticals, Inc. (CASI) - 424B3 SEC Filings 10/06/1999
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 10/05/1999
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/16/1999
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 08/10/1999
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 08/10/1999
CASI Pharmaceuticals, Inc. (CASI) - 424B3 SEC Filings 07/07/1999
CASI Pharmaceuticals, Inc. (CASI) - S-3/A SEC Filings 06/29/1999
CASI Pharmaceuticals, Inc. (CASI) - S-3 SEC Filings 06/08/1999
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 05/21/1999
CASI Pharmaceuticals, Inc. (CASI) - 10-Q/A - Quarterly Report SEC Filings 05/20/1999
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/17/1999
CASI Pharmaceuticals, Inc. (CASI) - 10-K405/A - Current report SEC Filings 05/14/1999
CASI Pharmaceuticals, Inc. (CASI) - 10-K405/A - Current report SEC Filings 04/30/1999
CASI Pharmaceuticals, Inc. (CASI) - 10-K405/A - Current report SEC Filings 04/14/1999
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 04/13/1999
CASI Pharmaceuticals, Inc. (CASI) - 10-K405 - Current report SEC Filings 03/31/1999
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 02/26/1999
CASI Pharmaceuticals, Inc. (CASI) - 8-K - Current report SEC Filings 02/11/1999
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 02/04/1999
CASI Pharmaceuticals, Inc. (CASI) - SC 13D/A SEC Filings 01/29/1999
CASI Pharmaceuticals, Inc. (CASI) - SC 13D SEC Filings 01/29/1999
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 12/21/1998
CASI Pharmaceuticals, Inc. (CASI) - SC 13D SEC Filings 11/13/1998
CASI Pharmaceuticals, Inc. (CASI) - S-8 SEC Filings 11/10/1998
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 10/30/1998
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 10/29/1998
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/12/1998
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 05/22/1998
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/15/1998
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 05/11/1998
CASI Pharmaceuticals, Inc. (CASI) - PRE 14A SEC Filings 05/08/1998
CASI Pharmaceuticals, Inc. (CASI) - 10-K405/A - Current report SEC Filings 04/30/1998
CASI Pharmaceuticals, Inc. (CASI) - 10-K405 - Current report SEC Filings 03/31/1998
CASI Pharmaceuticals, Inc. (CASI) - SC 13G/A SEC Filings 02/06/1998
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/13/1997
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 08/14/1997
CASI Pharmaceuticals, Inc. (CASI) - DEF 14A SEC Filings 05/23/1997
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 05/15/1997
CASI Pharmaceuticals, Inc. (CASI) - 10-K/A - Current report SEC Filings 04/30/1997
CASI Pharmaceuticals, Inc. (CASI) - S-8 SEC Filings 04/29/1997
CASI Pharmaceuticals, Inc. (CASI) - PRE 14A SEC Filings 04/18/1997
CASI Pharmaceuticals, Inc. (CASI) - 10-K405 - Current report SEC Filings 04/10/1997
CASI Pharmaceuticals, Inc. (CASI) - NT 10-K - Current report SEC Filings 04/01/1997
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 02/14/1997
CASI Pharmaceuticals, Inc. (CASI) - SC 13G SEC Filings 02/04/1997
CASI Pharmaceuticals, Inc. (CASI) - 10-Q - Quarterly Report SEC Filings 11/14/1996
CASI Pharmaceuticals, Inc. (CASI) - 10QSB SEC Filings 08/14/1996
CASI Pharmaceuticals, Inc. (CASI) - SC 13D SEC Filings 06/27/1996
CASI Pharmaceuticals, Inc. (CASI) - 424B1 SEC Filings 06/13/1996
CASI Pharmaceuticals, Inc. (CASI) - S-1/A SEC Filings 06/11/1996
CASI Pharmaceuticals, Inc. (CASI) - S-1/A SEC Filings 06/07/1996
CASI Pharmaceuticals, Inc. (CASI) - S-1/A SEC Filings 05/17/1996
CASI Pharmaceuticals, Inc. (CASI) - 8-A12G SEC Filings 05/14/1996

Press Releases

StockPrice Release
Casi pharmaceuticals appoints david cory as chief executive officer to lead u.s. company focused on clinical development of cid-103, a potential best in class anti-cd38 program 07/21/2025
Casi pharmaceuticals provides business and clinical update 05/19/2025
Casi pharmaceuticals announces first quarter 2025 business and financial results 05/16/2025
Casi pharmaceuticals enters into definitive agreement for the divestiture of assets in china 05/12/2025
Casi pharmaceuticals receives nasdaq deficiency notice regarding minimum market value requirement 05/07/2025
Casi pharmaceuticals announces receipt of an updated non-binding proposal to acquire entire china business of the company 04/03/2025
Casi pharmaceuticals announces fourth quarter and full-year 2024 business and financial results 03/31/2025
Casi announces first patient dosed in phase 1/2 clinical trial of cid-103 in immune thrombocytopenia 01/06/2025
Casi pharmaceuticals announces third quarter 2024 business and financial results 11/15/2024
Casi pharmaceuticals receives cta approval from china's nmpa for cid-103 in immune thrombocytopenia 10/24/2024
Casi pharmaceuticals to participate in the 2024 h.c. wainwright global investment conference 09/04/2024
Casi pharmaceuticals announces second quarter 2024 business and financial results 08/16/2024
Casi pharmaceuticals reports development relating to its disputes with juventas 07/19/2024
Casi pharmaceuticals announces appointment of daniel lang, md as cfo and svp 07/08/2024
Casi pharmaceuticals announces plan to submit ind application for cid-103, an anti-cd 38 antibody in antibody-mediated rejection, and receipt of a non-binding proposal to acquire entire china business of the company 06/26/2024
Casi pharmaceuticals announces $15 million private placement financing by venrock healthcare capital partners, foresite capital, panacea venture and dr. wei-wu he 06/26/2024
Casi pharmaceuticals receives fda clearance on the investigational new drug (ind) application for cid-103 in immune thrombocytopenia (itp) 05/15/2024
Casi pharmaceuticals announces first quarter 2024 business and financial results 05/14/2024
Casi pharmaceuticals reports development relating to its disputes with juventas 04/08/2024
Casi pharmaceuticals announces fourth quarter and full-year 2023 business and financial results 03/28/2024
Casi pharmaceuticals report positive interim phase 1 data for bi-1206 in the treatment of relapsed/refractory indolent non-hodgkin's lymphoma in china 03/05/2024
Casi pharmaceuticals announces first dosing of folotyn® in china 02/16/2024
Casi pharmaceuticals announces third quarter 2023 business and financial updates 11/14/2023
Casi pharmaceuticals announces market approval of cnct19 by china nmpa 11/08/2023
Casi pharmaceuticals announces second quarter 2023 business and financial updates 08/11/2023
Mundipharma international corporation limited, mundipharma medical company, and acrotech biopharma inc. enter agreement to transfer license of folotyn® (pralatrexate) in china to casi pharmaceuticals 08/01/2023
Casi pharmaceuticals acquires global intellectual property rights to cleave therapeutics' vcp/p97 inhibitor cb-5339 07/20/2023
Casi pharmaceuticals files annual report on form 20-f for fiscal year 2022 04/26/2023
Casi pharmaceuticals announces fourth quarter and full-year 2022 financial results 04/26/2023
Casi pharmaceuticals completes redomiciliation merger 03/21/2023
Casi pharmaceuticals and cleave therapeutics announce clinical trial application approval for cb-5339 in patients with multiple myeloma in china 01/06/2023
Casi pharmaceuticals' partner juventas announces new drug application for cnct19 accepted by china national medical products administration 12/15/2022
Casi pharmaceuticals announces exit of juventas investment to strengthen balance sheet 09/23/2022
Casi pharmaceuticals and bioinvent announce dosing of first patient in bi-1206 phase 1 clinical trial for the treatment of relapsed/refractory non-hodgkin's lymphoma in china 09/07/2022
Casi pharmaceuticals to report second quarter 2022 financial results and host conference call august 12, 2022 08/05/2022
Casi pharmaceuticals announces its partner, precision autoimmune therapeutics co., ltd has completed first-round financing of $21 million 07/08/2022
Casi pharmaceuticals announces reverse stock split 05/26/2022
Casi pharmaceuticals enteres into sublicense agreement with tianshi pharmaceuticals for anti-cd38 monoclonal antibody (mab) cid-103 in autoimmune field 05/24/2022
Casi pharmaceuticals statement on status under holding foreign companies accountable act 04/01/2022
Casi pharmaceuticals announces renewal of exclusive distribution agreement for evomela® in china 03/04/2022
Casi pharmaceuticals announces cnct19 (cd19 car-t) granted orphan drug designation by the u.s. fda 01/18/2022
Casi pharmaceuticals, receives nasdaq deficiency notice 01/03/2022
Casi pharmaceuticals announces stock repurchase program 12/17/2021
Bioinvent and casi pharmaceuticals announce cta approval for clinical studies of bi-1206 in nhl in china 12/10/2021
Casi pharmaceuticals announces partner juventas completion of series c financing of $63 million (rmb410 million) for acceleration of cnct19 pivotal trials and commercialization 10/25/2021
Casi pharmaceuticals, inc. to participate in oppenheimer fall healthcare life sciences & medtech summit 09/20/2021
Casi pharmaceuticals to report second quarter 2021 financial results and host conference call august 12, 2021 08/10/2021
Casi pharmaceuticals announces dosing of first patient of cid-103 in phase 1 clinical trial for relapsed or refractory multiple myeloma 06/10/2021
Casi pharmaceuticals, inc. to participate in jefferies virtual healthcare conference 05/27/2021
Casi pharmaceuticals to report first quarter 2021 financial results and host conference call may 13, 2021 05/11/2021
Casi pharmaceuticals announces full year 2020 financial results 03/30/2021
Casi pharmaceuticals announces pricing of $32,500,000 public offering of common stock 03/24/2021
Casi pharmaceuticals announces proposed public offering of common stock 03/23/2021
Casi pharmaceuticals to host business update call march 12, 2021 03/11/2021
Casi pharmaceuticals partner, bioinvent, to host key opinion leader call on bi-1206 for relapsed or refractory non-hodgkin's lymphoma 01/21/2021
Casi pharmaceuticals announces cnct19 (cd19 car-t) receives china breakthrough therapy designation 12/23/2020
Casi pharmaceuticals announces partner juventas completes $65 million financing and initiates registration study for cnct19 (cd19 car-t) 11/18/2020
Casi pharmaceuticals announces restructuring of partnership with juventas cell therapy 09/29/2020
Casi pharmaceuticals, wuxi jintou huicun jv enter into construction project contract 09/02/2020
Casi pharmaceuticals says unit entered into a loan agreement with juventas 08/19/2020
Casi pharmaceuticals reports q2 revenue $2.7 million 08/10/2020
Casi pharmaceuticals announces pricing of $38,000,000 public offering of common stock 07/22/2020
Casi pharmaceuticals announces proposed public offering of common stock 07/21/2020
2020 insights into the global multiple myeloma market and competitive landscape - researchandmarkets.com 06/26/2020
Casi pharmaceuticals reports first quarter 2020 financial results 05/11/2020
Casi pharmaceuticals announces full year 2019 financial results 03/16/2020
Casi pharmaceuticals says cfo george chi's employment will cease effective february 21 02/20/2020
China national medical product administration approves casi pharmaceuticals's cnct19 (cd19 car-t) clinical trial applications 12/03/2019
Casi pharmaceuticals, inc. announces retirement of ken k. ren from the board of directors 11/12/2019
Casi pharmaceuticals qtrly loss per share $0.10 11/12/2019
Casi pharmaceuticals, inc. reports unaudited consolidated financial results for the third quarter and nine months ended september 30, 2019 11/11/2019
Casi pharmaceuticals, inc. announces an exclusive distribution agreement with pharmathen global bv 11/06/2019
Casi pharma enters into an exclusive distribution license deal with pharmathen global bv 11/01/2019
Casi pharmaceuticals, inc. enters into exclusive distribution license agreement with pharmathen global bv 10/31/2019
Spectrum pharmaceuticals out-licenses rights for greater china to casi pharmaceuticals for three of its drugs 09/18/2014

More Headlines

News
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the first patient has been dosed in the Phase 1/2 trial to evaluate the safety and tolerability of CID-103 in adult patients with chronic Immune Thrombocytopenia (ITP) in China. "Dosing the first patient in our phase 1/2 study marks a significant milestone for both CID-103 program and chronic ITP patients who have limited treatment options," said Dr. Wei-Wu He, Chairman and CEO of CASI, "The rapid execution underscores our commitment to accelerating clinical development. 01/06/2025
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024. Dr. Wei-Wu He, Chairman and CEO of CASI, said "The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases. 11/15/2024
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) to proceed with a phase 1/2 study of CID-103 in adults patients with chronic Immune Thrombocytopenia (ITP) in China. This China study is part of the global study that was approved by the US FDA in May 2024. 10/24/2024
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE BEIJING , Sept. 4, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today announced its participation in the H.C. 09/04/2024
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS BEIJING , Aug. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended June 30, 2024. "The second quarter of 2024 was a period of significant progress for CASI as we shifted our Company's strategy to the development of therapeutics for organ transplant rejection and autoimmune disease," said Dr. Wei-Wu He, Chairman and CEO of CASI Pharmaceuticals. 08/16/2024
3 Promising Biotech Stocks You Can Pick Up for Less Than $10 What could be better than viable enterprises within the biotechnology industry? Try biotech stocks under $10. 07/29/2024
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS BEIJING , July 19, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link: https://www.sec.gov/Archives/edgar/data/1962738/000110465924080958/tm2419826d1_6k.htm About CASI Pharmaceuticals CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. 07/19/2024
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP BEIJING , July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8 th, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. 07/08/2024
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news. 06/27/2024
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company BEIJING , June 26, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that the Company is planning to submit an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for CID-103 for the treatment of antibody-mediated rejection ("AMR") in kidney transplant recipients by the end of 2024. CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that has demonstrated an encouraging preclinical efficacy and safety profile compared to other anti-CD38 monoclonal antibodies. 06/26/2024
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He BEIJING , June 26, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that it has entered into securities purchase agreements with certain investors for a private investment in public equity financing (the "PIPE Transaction") that is expected to result in aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other private placement expenses. The PIPE Transaction is being led by Venrock Healthcare Capital Partners and Foresite Capital, with participation by Panacea Venture and Dr. Wei-Wu He, the Chairman of the board of directors and Chief Executive Officer of the Company and his family trust. 06/26/2024
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) BEIJING , May 15, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced today the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP). On May 13, 2024 CASI received a letter from FDA indicating that study may proceed. 05/15/2024
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS BEIJING , May 14, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the three months ended March 31, 2024. In the first quarter of 2024, CASI's total revenue was $3.4 million. 05/14/2024
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS BEIJING , April 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link: https://www.sec.gov/Archives/edgar/data/1962738/000196273824000014/tmb-20240408x6k.htm About CASI Pharmaceuticals CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. 04/08/2024
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS BEIJING , March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023. CASI reported fourth quarter 2023 revenue of $6.9 million for EVOMELA®, 33% lower than the same period in 2022. 03/28/2024
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China BEIJING and LUND, Sweden , March 5, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for BI-1206 in combination with rituximab in patients with relapsed/refractory (R/R) indolent Non-Hodgkin's Lymphoma (iNHL) in the ongoing development program in China. BI-1206 is a first-in-class fully human monoclonal antibody (mAb) that targets FcγRIIB. 03/05/2024
CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA BEIJING , Feb. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced the administration of the first dose of FOLOTYN® (Pralatrexate Injection) to a patient in China. This remarks a pivotal step in CASI's commitment to addressing critical medical needs in peripheral T-cell lymphoma in China market. 02/16/2024
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES BEIJING , Nov. 14, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the third quarter ended September 30, 2023. Dr. Wei-Wu He, Chairman and CEO of CASI Pharmaceuticals, stated, "We are delighted to announce that our partner Juventas has received approval from the China National Medical Products Administration (NMPA) for Inaticabtagene Autoleucel (anti-CD 19 CAR-T Cell Therapy) for the treatment of B-cell acute lymphoblastic leukemia (r/r B-ALL) in China. 11/14/2023
CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA BEIJING , Nov. 8, 2023 /PRNewswire/ -- CASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy Ltd. (Juventas). 11/08/2023
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES BEIJING , Aug. 11, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the quarter ended June 30, 2023. Wei-Wu He, Ph.D. 08/11/2023
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals BEIJING , Aug. 1, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of an Assignment Agreement (the "Agreement") with Mundipharma International Corporation Limited ("MICL"), Mundipharma Medical Company ("MMCo"), and Acrotech Biopharma Inc. ("Acrotech") for the commercialization of FOLOTYN® (Pralatrexate) in the People's Republic of China ("China"). FOLOTYN® (Pralatrexate) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma ("PTCL"). 08/01/2023
CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 BEIJING , July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the United States ("US") CB-5339 Investigational New Drug ("IND") application. 07/20/2023
Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China Shares of Casi Pharmaceuticals Inc. CASI, +3.63% were up 10% in premarket trading on Friday after the company said China will allow a Phase 1 clinical trial evaluating a multiple myeloma drug developed by the privately held Cleave Therapeutics. The study is expected to start this year. 01/06/2023
CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimates CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 25.49% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? 11/14/2022
ALJ Regional Hldgs (NASDAQ:ALJJ), CASI Pharmaceuticals (NASDAQ:CASI) – $2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying The Dow Jones closed higher by around 193 points on Thursday. Investors, meanwhile, focused on some notable insider trades. 09/09/2022
CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades. 08/29/2022
CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q2 2022 Results - Earnings Call Transcript CASI Pharmaceuticals, Inc. (NASDAQ:CASI ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET Company Participants Wei Zhang – Vice President Wei-Wu He – Chairman and Chief Executive Officer Alex Zukiwski – Executive Vice President and Chief Medical Officer Larry Zhang – President Rui Zhang – Vice President-Business Development Conference Call Participants Leland Gershell – Oppenheimer Sean Lee – H.C. Wainwright Operator Good day everyone and welcome to the CASI Pharmaceuticals' Second Quarter 2022 Earnings Conference Call. 08/12/2022
CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 13.85% and 19.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? 08/12/2022
CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022 ROCKVILLE, Md. and BEIJING , Aug. 5, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the financial results for the second quarter of 2022, at 8:00 A.M. 08/05/2022
Why Is CASI Pharmaceuticals (CASI) Stock Up 700% Today? CASI Pharmaceuticals (CASI) stock rocketed higher in pre-market trading this morning but it's not due to any positive news from the company. The post Why Is CASI Pharmaceuticals (CASI) Stock Up 700% Today? 06/02/2022
CASI Pharmaceuticals stock falls after reverse split takes effect Shares of CASI Pharmaceuticals Inc. CASI, +18.01% are actually falling in premarket trading Thursday, as a 1-for-10 reverse stock split took effect. While some quote services may still be showing a big gain for the Maryland-based biopharmaceutical company's stock, closed Wednesday at a pre-split price of 40.63 cents, meaning a 1-for-10 reverse split would adjust the price to $4.063. 06/02/2022
CASI Pharmaceuticals, Inc.'s (CASI) CEO Wei-Wu He on Q1 2022 Results - Earnings Call Transcript CASI Pharmaceuticals, Inc. (NASDAQ:CASI ) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Wei-Wu He - Chairman and Chief Executive Officer Wei Zhang - President Larry Zhang - President Alexander Zukiwski - Executive Vice President and Chief Medical Officer James Goldschmidt - Chief Business Development Officer Conference Call Participants Justin Zelin - BTIG Sean Lee - HC Wainwright Trevor Allred - Oppenheimer Operator Good morning everyone and welcome to the CASI Pharmaceuticals First Quarter 2022 Business Update and Financial Results Conference Call. All participants will be in a listen-only mode. 05/12/2022
CASI Pharmaceuticals, Inc. (CASI) Reports Q1 Loss, Misses Revenue Estimates CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 40% and 0.96%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? 05/12/2022
Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting stage, the framework from the China Securities Regulatory Commission and other national. 04/01/2022
CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q4 2021 Results - Earnings Call Transcript CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q4 2021 Results - Earnings Call Transcript 03/28/2022
CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2021 Results - Earnings Call Transcript CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2021 Results - Earnings Call Transcript 11/12/2021
CASI Pharmaceuticals Earnings Preview CASI Pharmaceuticals (NASDAQ:CASI) is set to give its latest quarterly earnings report on Friday, 2021-11-12. Here's what investors need to know before the announcement. 11/11/2021
CASI Pharmaceuticals, Inc. (CASI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 11/01/2021
CASI Pharma (CASI) Sees Hammer Chart Pattern: Time to Buy? CASI Pharma (CASI) has been struggling lately, but the selling pressure may be coming to an end soon. 10/06/2021
CASI Pharmaceuticals, Inc. To Participate In Oppenheimer Fall Healthcare Life Sciences & MedTech Summit ROCKVILLE, Md. and BEIJING, Sept. 09/20/2021
Penny Stocks For Your Biotech Watch List In September 2021 Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 09/15/2021
Trending Penny Stocks To Buy For Under $3 Right Now Are these penny stocks worth the risk? The post Trending Penny Stocks To Buy For Under $3 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 08/23/2021
CASI Pharmaceuticals Shares Increase Over 15% Pre-Market: Why It Happened The shares of CASI Pharmaceuticals, Inc. (Nasdaq: CASI) increased by over 16% pre-market. This is why it happened. 08/23/2021
CASI Pharmaceuticals, Inc. (CASI) CEO Dr. Wei-Wu He on Q2 2021 Results - Earnings Call Transcript CASI Pharmaceuticals, Inc. (CASI) CEO Dr. Wei-Wu He on Q2 2021 Results - Earnings Call Transcript 08/13/2021
CASI Pharmaceuticals To Report Second Quarter 2021 Financial Results And Host Conference Call August 12, 2021 ROCKVILLE, Md. and BEIJING, Aug. 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the second quarter highlights at 8:00 a.m. 08/10/2021
Analysts Estimate CASI Pharmaceuticals, Inc. (CASI) to Report a Decline in Earnings: What to Look Out for CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 08/02/2021
CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma ROCKVILLE, Md. and BEIJING, June 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced First-Patient-In in the Phase 1 dose escalation and expansion study of CID-103, an investigational novel anti-CD38 monoclonal antibody, in patients with previously treated, relapsed or refractory multiple myeloma. 06/10/2021
CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare Conference ROCKVILLE, Md. and BEIJING, May 27, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He, Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the Jefferies Virtual Healthcare Conference. 05/27/2021
Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10 While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. 05/22/2021
CASI Pharmaceuticals, Inc. (CASI) CEO Dr. Wei-Wu He on Q1 2021 Results - Earnings Call Transcript CASI Pharmaceuticals, Inc. (CASI) CEO Dr. Wei-Wu He on Q1 2021 Results - Earnings Call Transcript 05/19/2021
CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021 ROCKVILLE, Md. and BEIJING, May 11, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the first quarter highlights at 8:00 a.m. 05/11/2021
CASI Stock: $3.80 Target By Mizuho The shares of CASI Pharmaceuticals Inc (NASDAQ: CASI) have received a $3.80 price target by Mizuho. These are the details. 04/30/2021
3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383% Penny stocks to buy according to top Wall Street analysts The post 3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383% appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 04/30/2021
CASI Stock Price Increased Over 10% Pre-Market: Why It Happened The stock price of CASI Pharmaceuticals, Inc. (Nasdaq: CASI) increased by over 10% pre-market. This is why it happened. 03/31/2021
CASI Pharmaceuticals Announces Full Year 2020 Financial Results ROCKVILLE, Md. and BEIJING, March 30, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2020 and provided an update on key highlights for 2021. 03/30/2021
Why CASI Pharmaceuticals Is Crashing Today Investors don't like that the company is hitting up the market for more cash. 03/24/2021
CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock ROCKVILLE, Md. and BEIJING, March 24, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 15,853,658 shares of its common stock at a price to the public of $2.05 per share. 03/24/2021
CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock ROCKVILLE, Md. and BEIJING, March 23, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. 03/23/2021
CASI Pharmaceuticals To Host Business Update Call March 12, 2021 ROCKVILLE, Md. and BEIJING, March 11, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call at 8:00 a.m. 03/11/2021
CASI Pharmaceuticals To Develop CB-5339 In Cancer Indications In China Cleave Therapeutics Inc has out-licensed CB-5339 to CASI Pharmaceuticals Inc (NASDAQ: CASI) in mainland China, Taiwan, Hong Kong, and Macau. Cleave and CASI will develop CB-5339 in both hematological malignancies and solid tumors under the terms of the agreement, with CASI responsible for development and commercialization in China and associated markets. 03/08/2021
CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation ROCKVILLE, Md., and BEIJING, Dec. 23, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that the Chinese Center for Drug... 12/23/2020
CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T) ROCKVILLE, Md. and BEIJING, Nov. 18, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces partner Juventas has completed the... 11/18/2020
CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2020 Results - Earnings Call Transcript CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2020 Results - Earnings Call Transcript 11/10/2020
Week In Review: CStone Out-Licenses Ex-China Rights To 2 Immunotherapies In $1.3 Billion Deal CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Sweden's BioInvent in a $95 million deal. 11/01/2020
CASI Pharmaceuticals Inc (CASI) Q2 2020 Earnings Call Transcript Earlier today, CASI issued a press release providing the details of our financial results for the quarter ended June 30, 2020, as well as a corporate and clinical update. The press release is available in the Investor Relations section of our website at casipharmaceuticals.com. 08/11/2020
CASI Pharmaceuticals: Q2 Earnings Insights Shares of CASI Pharmaceuticals (NASDAQ:CASI) moved higher by 1.6% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 43.75% year over year to ($0.09), which missed the estimate of ($0.08).Revenue of $2,671,000 higher by 0.00% year over year, which missed the estimate of $3,750,000.Outlook CASI Pharmaceuticals hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: Aug 10, 2020View more earnings on CASITime: 04:30 PMET Webcast URL: https://www.casipharmaceuticals.com/investor-relations/events/Technicals Company's 52-week high was at $3.82Company's 52-week low was at $1.15Price action over last quarter: Up 10.34%Company Overview CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.See more from Benzinga * Recap: Chimerix Q2 Earnings * Recap: Momenta Pharmaceuticals Q2 Earnings * Recap: Amicus Therapeutics Q2 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 08/10/2020
CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results 08/10/2020
CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results and business highlights for the second quarter of 2020. 08/10/2020
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus... 08/09/2020
CASI Pharmaceuticals Inc (NASDAQ:CASI) CEO Buys $5,609,609.40 in Stock CASI Pharmaceuticals Inc (NASDAQ:CASI) CEO Wei-Wu He purchased 2,952,426 shares of the company’s stock in a transaction dated Wednesday, July 22nd. The shares were purchased at an average cost of $1.90 per share, for a total transaction of $5,609,609.40. Following the transaction, the chief executive officer now directly owns 4,836,523 shares in the company, valued […] 07/27/2020
Week In Review: BeiGene Signs $540 Million Deal For China Rights To 3 HBV Candidates Beijing's BeiGene in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus from Assembly Biosciences in a $540 million agreement. 07/26/2020
CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $1.90 per share. CASI has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock. The offering is expected to close on or about July 24, 2020, subject to satisfaction of customary closing conditions. The gross proceeds to CASI from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $38.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by CASI. 07/22/2020
The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD) Assembly Biosciences Inc (NASDAQ: ASMB) Bio-Rad Laboratories, Inc. (NYSE: BIO)... 07/22/2020
CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, CASI expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. There can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares of common stock in the offering will be sold by CASI. 07/21/2020
Here's What CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shareholder Ownership Structure Looks Like A look at the shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) can tell us which group is most powerful... 07/09/2020
2020 Insights into the Global Multiple Myeloma Market and Competitive Landscape - ResearchAndMarkets.com The 06/26/2020
CASI Pharmaceuticals Submits a Clinical Trial Application in the UK for a Phase 1 Study of its Anti-38 Monoclonal 06/08/2020
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it submitted a Clinical Trial Application (CTA) (IND) with the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for CID-103, its novel anti-CD38 monoclonal antibody for the treatment of multiple myeloma and other hematological malignancies. 06/08/2020
CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business update at the Jefferies 2020 Healthcare Conference on Thursday, June 4, 2020, at 4:00 p.m. ET. The conference will be held in a virtual meeting format. 06/02/2020
Do Hedge Funds Love CASI Pharmaceuticals Inc (CASI)? Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […] 05/31/2020
Wei-Wu He Is The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) And They Just Picked Up 32% More Shares Those following along with CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will no doubt be intrigued by the recent purchase... 05/25/2020
70 Biggest Movers From Yesterday 05/21/2020
Casi Pharmaceuticals Inc (CASI) Chairman and CEO Wei-wu He Bought $–94,…96 of Shares 05/21/2020
52 Stocks Moving In Wednesday's Mid-Day Session 05/20/2020
Casi Pharmaceuticals Inc (CASI) Chairman and CEO Wei-wu He Bought $864,696 of Shares 05/19/2020
Earnings Update: CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Just Reported And Analysts Are Boosting Their Estimates CASI Pharmaceuticals, Inc. (NASDAQ:CASI) just released its latest first-quarter results and things are looking... 05/14/2020
CASI Pharmaceuticals: 2-Year Price Lows Make For Intriguing Risk-On Buy CASI is focused on developing and commercialising drugs for the Chinese market most notably within the field of hematology/oncology using an innovative in-licen 05/13/2020
Upgrade: Analysts Just Made A Notable Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shareholders will have a reason to smile today, with the analysts making... 05/12/2020
CASI Pharmaceuticals Q1 EPS $(0.090), Same YoY 05/11/2020
CASI Pharmaceuticals Announces First Quarter 2020 Financial Results CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the first quarter of 2020. 05/11/2020
CASI: A Change in Strategy By Beth Senko, CFA NASDAQ:CASI READ THE FULL CASI RESEARCH REPORT CASI Pharmaceuticals (NASDAQ:CASI) signaled a shift in its business strategy in March – focusing its efforts on its hematology franchise and deemphasizing its ANDA portfolio. This change scales back CASI’s initial broad-reaching goal to be the leading provider of high quality proprietary, licensed and ANDA pharmaceuticals to the 05/08/2020
CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business update at the Solebury Trout Virtual Global Healthcare Series. During the 25-minute presentation, participants will be able to submit questions electronically with answers provided by the discretion of the company on an individual basis afterwards. Details are as follows: 04/07/2020
Solebury Trout Announces Additional Virtual Conference Presentations from Life Science Companies on April 7, 2020 NEW YORK, NY / ACCESSWIRE / April 6, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a fourth day of presentations as part ... 04/06/2020
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Analysts Just Slashed This Year's Estimates Market forces rained on the parade of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shareholders today, when the analysts... 03/31/2020
Daily Insider Ratings Round Up 3/27/20 Tables of the top insider purchases and sales filed with the SEC on 3/27/20, based on dollar value. Dollar values often do not equate with significance when it 03/29/2020
Insider Buying: The CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Chairman & CEO Just Bought US$1.1m Worth Of Shares Those following along with CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will no doubt be intrigued by the recent purchase... 03/29/2020
Casi Pharmaceuticals Inc (CASI) Chairman and CEO Wei-wu He Bought $–.– million of Shares 03/27/2020
HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $3.5 03/24/2020
Daily Insider Ratings Round Up 3/19/20 Tables of the top insider purchases and sales filed with the SEC on 3/19/20, based on dollar value. Dollar values often do not equate with significance when it 03/20/2020
Casi Pharmaceuticals Inc (CASI) Chairman and CEO Wei-wu He Bought $–.5 million of Shares 03/19/2020
CASI Pharmaceuticals Announces Full Year 2019 Financial Results CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2019, and provided a business update. 03/16/2020
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo... 03/13/2020
Stocks That Hit 52-Week Lows On Thursday 03/12/2020
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics... 03/12/2020
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics... 03/12/2020
Stocks That Hit 52-Week Lows On Wednesday During Wednesday's morning session, 690 stocks hit new 52-week lows. Intriguing Points: Boeing (NYSE: BA) was the biggest company on a market cap basis to set a new... 03/11/2020
Ligand’s Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that today’s scheduled in-person presentation at the Barclays Global Healthcare Conference in Miami Beach was changed by conference organizers to a webcast only, as the conference has been reconfigured. The webcast will take place as previously 03/10/2020
20 Healthcare Stocks Moving In Monday's Session 03/09/2020
Stock Charts For The Coming Week Robert Desmond discusses the charts for the new trading week. 03/08/2020
Stock Charts For The Coming Week 03/08/2020
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19 Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS 03/05/2020
Stocks That Hit 52-Week Lows On Wednesday Wednesday's morning session saw 132 companies set new 52-week lows. Intriguing Points: HDFC Bank (NYSE: HDB) was the biggest company by market cap to set a new 52-... 03/04/2020
Did Changing Sentiment Drive CASI Pharmaceuticals's (NASDAQ:CASI) Share Price Down By 47%? It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do... 03/02/2020
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (... 02/28/2020
Stocks That Hit 52-Week Lows On Friday 02/28/2020
Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces an update to its financial outlook and raises its 2020 financial guidance. Ligand now expects 2020 total revenues to be approximately $133 million and diluted EPS to be $3.62, up from previous guidance for total revenues of approximately $128 02/27/2020
Stocks That Hit 52-Week Lows On Thursday 02/27/2020
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arcus Biosciences Inc (NYSE: RCUS ) BELLUS Health Inc (NASDAQ: BLU ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Masimo Corporation (NASDAQ: MASI ) (announced its fourth-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Relmada Therapeutics Inc (NASDAQ: RLMD ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced $287.5-million debt offering) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Feb. 13) Scpharmaceuticals Inc (NASDAQ: SCPH ) Soligenix, Inc. 02/21/2020
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc. 02/20/2020
Casi Pharmaceuticals Says Company's CFO George Chi's Employment Will Cease Effective February 21, 2020 02/20/2020
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: AGRX ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptose Biosciences Inc (NASDAQ: APTO ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) Avrobio Inc (NASDAQ: AVRO ) Beam Therapeutics Inc (NASDAQ: BEAM ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) NeoGenomics, Inc. (NASDAQ: NEO ) Novartis AG (NYSE: NVS ) Ocular Therapeutix Inc (NASDAQ: OCUL ) PAVmed Inc (NASDAQ: PAVM ) Penumbra Inc (NYSE: PEN ) Prevail Therapeutics Inc (NASDAQ: PRVL )(reacted to the FDA according Orphan Drug Designation to its experimental gene therapy PR001 for treating Gaucher disease) PTC Therapeutics, Inc (NASDAQ: PTCT ) Repligen Corporation (NASDAQ: RGEN ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) West Pharmaceutical Services Inc. 02/13/2020
Stocks That Hit 52-Week Lows On Wednesday 02/12/2020
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) )(reacted to better-than-expected results and comments that its deal to be acquired by AbbVie is on track to close by the first quarter) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) ChemoCentryx Inc (NASDAQ: CCXI ) Co-Diagnostics Inc (NASDAQ: CODX )(announced sales of its new coronavirus test ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD )(reacted to positive data readout from early-stage study of experimental drug to treat eye disorders) Masimo Corporation (NASDAQ: MASI ) Novartis AG (NYSE: NVS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Revance Therapeutics Inc (NASDAQ: RVNC ) ResMed Inc. 02/11/2020
Stocks That Hit 52-Week Lows On Monday 02/10/2020
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues. 02/07/2020
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up 02/07/2020
The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ALEC ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Applied Therapeutics Inc (NASDAQ: APLT ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT )(IPOed Jan. 31) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(IPOed Jan. 30) ChemoCentryx Inc (NASDAQ: CCXI ) Eli Lilly And Co (NYSE: LLY ) Fate Therapeutics Inc (NASDAQ: FATE ) Frequency Therapeutics Inc (NASDAQ: FREQ ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Hologic, Inc. (NASDAQ: HOLX ) Insmed Incorporated (NASDAQ: INSM )(reacted to positive analyst actions following a positive data readout reported Monday) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Molecular Templates Inc (NASDAQ: MTEM ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Quest Diagnostics Inc (NYSE: DGX ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) ResMed Inc. 02/05/2020
Stocks That Hit 52-Week Lows On Tuesday On Tuesday morning, 82 companies hit new 52-week lows. Things to Consider: Royal Dutch Shell (OTC: RYDBF) is the largest company in terms of market cap to set a new 52-... 02/04/2020
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences Inc (NASDAQ: APTO ) Catalent Inc (NYSE: CTLT ) ( announced a deal to buy cell and gene therapy CDMO MasTherCell and forecast-beating second quarter results) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Molecular Templates Inc (NASDAQ: MTEM ) Orgenesis Inc (NASDAQ: ORGS ) (announced sale of subsidiary MasTherCell to Catalent) Profound Medical Corp (NASDAQ: PROF ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) Theravance Biopharma Inc (NASDAQ: TBPH ) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 3.) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Avanos Medical Inc (NYSE: AVNS ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) (moved along with China pharmaceutical stocks due to coronavirus) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc. (NASDAQ: GALT ) I-Mab (NASDAQ: IMAB ) (went public in mid-January) Intec Pharma Ltd (NASDAQ: NTEC ) TapImmune Inc. (NASDAQ: MRKR ) Omeros Corporation (NASDAQ: OMER ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) X4 … 02/04/2020
Stocks That Hit 52-Week Lows On Monday Monday's morning session saw 187 companies set new 52-week lows. Interesting Highlights: Xperi (NASDAQ: XPER) was the biggest company on a market cap basis to set a... 02/03/2020
23 Biotechnology Stocks Moving In Monday's After-Market Session 01/27/2020
What You Must Know About CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Beta Value Anyone researching CASI Pharmaceuticals, Inc. (NASDAQ:CASI) might want to consider the historical volatility of the... 01/26/2020
Have Insiders Been Buying CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Shares? We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The... 12/20/2019
Week In Review: Alphamab Oncology Plans $350 Million Hong Kong IPO 12/07/2019
CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that the China National Medical Product Administration (NMPA), has approved the clinical trial applications for CNCT19 (CD19 CAR-T) in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) submitted by its partner Juventas Cell Therapy Ltd., a biopharmaceutical company focused on cell therapy (Juventas). CASI previously reported its acquisition of exclusive worldwide commercial rights to CNCT19 from Juventas. Juventas has responsibility for the clinical development of CNCT19. 12/04/2019
CASI Pharma's CD19 CAR-T clinical trial applications OK'd in China 12/04/2019
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Path To Profitability CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI): CASI Pharmaceuticals, Inc., a pharmaceutical company, develops... 11/14/2019
CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results ROCKVILLE, Md. and BEIJING , Nov. 12, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical ... 11/12/2019
CASI Pharmaceuticals Q3 EPS $(0.1), Same YoY 11/12/2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly ROCKVILLE, Md. and BEIJING, Nov. 7, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces an exclusive distribution agreement with Pharmathen Global BV for the development and distribution of octreotide long acting injectable (LAI) microsphere in China. Octreotide LAI formulations are considered a standard of care for the treatment of acromegaly and for the control of symptoms associated with certain neuroendocrine tumors. 11/07/2019
CASI Pharmaceuticals Enters Exclusive Distribution Agreement With Pharmathen Global BV For The Development And Distribution Of Octreotide Long Acting Injectable Microsphere In China. 11/07/2019
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected. 11/06/2019
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down 11/06/2019
CASI Pharma 8-K Shows Co. Entered Exclusive License Distribution License Deal With Pharmathen To Develop, Distribute Octreotide Long-Acting Injectable Microsphere In China 11/01/2019
Week In Review: Investor Group Bids $4.6 Billion To Acquire China Biologic 09/21/2019
New president at CASI Pharma 09/19/2019
CASI Pharma Reports China's National Medical Product Administration Accepted Trial Application For Co.'s CD19 CAR-T Product 09/16/2019
CASI Pharmaceuticals (CASI) Investor Presentation - Slideshow 09/10/2019
Ligand Pharma Reports Partnership With CASI Pharma To Launch EVOMELA in China 08/12/2019
CASI Pharmaceuticals Q2 EPS $(0.16) Down From $(0.07) YoY 08/09/2019
Week In Review: Immunotherapies Dominate The Week's China Biopharma News 06/22/2019
CASI Pharma Acquires Worldwide Rights to Commercialize Anti-CD19 T-Cell Therapy From Juventas Cell Therapy, CASI to Invest RMB 80M in Juventas 06/17/2019
CASI Pharmaceuticals Q1 EPS $(0.09), Inline 05/15/2019
This Day In Market History: New York Times Article Suggests Cancer Cure By Year 2000 05/03/2019
Week In Review: Chi-Med Plans $500 Million Hong Kong IPO 04/20/2019
CASI Pharmaceuticals Obtains Global Rights To TSK011010 Anti-CD38 Monoclonal Antibody From Black Belt Therapeutics For €5M And An Equity Investment Of €2M 04/17/2019
50 Biggest Movers From Yesterday 04/09/2019
48 Stocks Moving In Monday's Mid-Day Session 04/08/2019
New CEO at CASI Pharma 04/02/2019
CASI Pharmaceuticals, Inc. - Common Stock Q4 EPS $(0.10) Down From $(0.08) YoY 03/29/2019
Week In Review: Inventis Closes $70 Million Financing To Develop 30 Novel Therapeutics 03/16/2019
CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection In China 03/13/2019
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS 03/09/2019
CASI Pharma Reports China National Medical Products Administration Approved CTA To Conduct Registration Trial For MARQIBO 03/07/2019
Report: Developing Opportunities within Pure Storage, Flowers Foods, Cognex, CASI ... 02/20/2019
CASI Pharmaceuticals Announces China National Medical Products Administration Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN 02/19/2019
CASI Pharmaceuticals (CASI) Presents At BIO CEO & Investor Conference - Slideshow 02/13/2019
22 Stocks Moving In Monday's Pre-Market Session 12/31/2018
52 Biggest Movers From Yesterday 12/13/2018
41 Stocks Moving In Wednesday's Mid-Day Session 12/12/2018
Week In Review: China Pharmas Announce Deals Worth $1.5 Billion 12/08/2018
56 Biggest Movers From Yesterday 12/04/2018
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection 12/03/2018
38 Stocks Moving In Friday's Mid-Day Session 11/30/2018
Week In Review: Alphamab Closes $100 Million Series A For Oncology Candidates 11/24/2018
55 Biggest Movers From Friday 11/19/2018
CASI Pharma Announces Will Build A GMP Manufacturing Site In Wuxi, China 11/16/2018
CASI Pharma Filing Shows Registration For ~9.1M Share Common Stock Offering Via Selling Shareholders 11/14/2018
64 Biggest Movers From Yesterday 10/31/2018
48 Biggest Movers From Yesterday 10/30/2018
RHT, GNW, WFT, ACB among midday movers (10/29/2018) 10/29/2018
56 Biggest Movers From Yesterday 10/25/2018
56 Biggest Movers From Yesterday 10/24/2018
CASI Pharma Reports Purchase Of HBV ANDA From Laurus Labs, No Terms Disclosed 10/23/2018
26 Stocks Moving In Thursday's Pre-Market Session 10/04/2018
CASI Pharmaceuticals Appoints Larry Zhang To President 10/02/2018
CASI Pharma Names George Chi CFO 09/28/2018
Week In Review: WuXi AppTec Files For $1 Billion+ Hong Kong IPO At $13 Billion Valuation 09/23/2018
CASI Pharmaceuticals Announces $48.5M Private Placement, Will Issue 9.048M Shares At Price Of $5.36/Share 09/14/2018
Factors of Influence in —…–8, Key Indicators and Opportunity within Steelcase, ... 08/27/2018
CASI Pharmaceuticals Q2 EPS $(0.12) Misses $(0.07) Estimate 08/14/2018
CASI Pharma S-3 Shows Registration For Offering Of ~17.28M Shares Of Common Stock Via Selling Holders 07/17/2018
Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index 07/05/2018
CASI Pharma Added To Russell 2000, 3000 And Microcap Indices 07/03/2018
44 Biggest Movers From Friday 07/02/2018
CASI Pharma Shares Fall ~7% Over Last Min., Not Seeing News To Justify Dip Lower; Shares Had Been Up ~10% For Session On No News 06/26/2018
25 Stocks Moving In Monday's Pre-Market Session 06/25/2018
Mid-Day Market Update: Dow Down Over 150 Points; CASI Pharmaceuticals Shares Spike Higher 06/21/2018
42 Biggest Movers From Yesterday 06/13/2018
CASI Pharmaceuticals Q1 EPS $(0.05) Misses $(0.01) Estimate 05/15/2018
Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, ... 05/07/2018
Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss 05/03/2018
25 Stocks Moving In Tuesday's Mid-Day Session 04/10/2018
30 Biggest Movers From Friday 04/09/2018
CASI Pharma Shares Up 22%, Rebounding From Yesterday's Weakness After Announcing Thursday That Chinese Regulators Agreed To Review Its EVOMELA Cancer Treatment 04/06/2018
UPDATE: CASI Says CDE AdComm Will Review EVOMELA Apr. 25-26 04/05/2018
18 Stocks Moving In Wednesday's Pre-Market Session 04/04/2018
Mid-Day Market Update: NASDAQ Down Over 2%; SELLAS Life Sciences Shares Spike Higher 04/02/2018
CASI Pharma Q4 EPS $(0.08) Misses $(0.02) Est. 03/29/2018
Daily Insider Ratings Round Up 3/23/18: IFF, CASI, RIBT, ADAP 03/27/2018
Week In Review: James Watson To Lead New Shenzhen Biopharma Research Center 03/25/2018
33 Biggest Movers From Yesterday 03/21/2018

Unlock

CASI Ratings Summary

CASI Quant Ranking